These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 10558530

  • 41. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Sep 29; 73(189):56487-91. PubMed ID: 18985960
    [Abstract] [Full Text] [Related]

  • 42. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May 21; 64(98):27666-93. PubMed ID: 10558542
    [Abstract] [Full Text] [Related]

  • 43. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May 17; 64(94):26657. PubMed ID: 10558515
    [Abstract] [Full Text] [Related]

  • 44. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May 12; 63(91):26127-9. PubMed ID: 10179335
    [Abstract] [Full Text] [Related]

  • 45. Medical devices; pediatric uses of devices; requirement for submission of information on pediatric subpopulations that suffer from a disease or condition that a device is intended to treat, diagnose, or cure; direct final rule. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2010 Apr 01; 75(62):16347-51. PubMed ID: 20383921
    [Abstract] [Full Text] [Related]

  • 46. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov 07; 65(216):66621-35. PubMed ID: 11503696
    [Abstract] [Full Text] [Related]

  • 47. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS.
    Fed Regist; 2004 Feb 23; 69(35):8105-7. PubMed ID: 14997866
    [Abstract] [Full Text] [Related]

  • 48. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep 09; 61(175):47413-23. PubMed ID: 10160337
    [Abstract] [Full Text] [Related]

  • 49. Antidiarrheal drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2003 Apr 17; 68(74):18869-82. PubMed ID: 12701600
    [Abstract] [Full Text] [Related]

  • 50. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
    Food and Drug Administration, HHS.
    Fed Regist; 2006 Nov 13; 71(218):66108-9. PubMed ID: 17099971
    [Abstract] [Full Text] [Related]

  • 51. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr 22; 63(77):19799-802. PubMed ID: 10179316
    [Abstract] [Full Text] [Related]

  • 52. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Dec 03; 64(232):67720-63. PubMed ID: 11010665
    [Abstract] [Full Text] [Related]

  • 53. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2003 Apr 17; 68(74):18861-9. PubMed ID: 12701599
    [Abstract] [Full Text] [Related]

  • 54. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug 31; 49(171):34448-51. PubMed ID: 10299643
    [Abstract] [Full Text] [Related]

  • 55. Medical device reporting: manufacturer reporting, importer reporting, user facility reporting, distributor reporting--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug 27; 63(166):45716-7. PubMed ID: 10182694
    [Abstract] [Full Text] [Related]

  • 56. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2003 Jun 09; 68(110):34273-93. PubMed ID: 12795305
    [Abstract] [Full Text] [Related]

  • 57. Microbiology devices; reclassification of Herpes simplex virus types 1 and 2 serological assays. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2009 Aug 25; 74(163):42773-5. PubMed ID: 19827226
    [Abstract] [Full Text] [Related]

  • 58. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan 02; 46(1):28-30. PubMed ID: 10324121
    [Abstract] [Full Text] [Related]

  • 59. Revisions to the general safety requirements for biological products; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Apr 20; 63(75):19431-4. PubMed ID: 10178870
    [Abstract] [Full Text] [Related]

  • 60. General requirements for blood, blood components, and blood derivatives; donor notification. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2001 Jun 11; 66(112):31165-77. PubMed ID: 11725787
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.